QBE shrugs off dour market conditions to grow its FY22 net profit by $20m

Nick Sundich Nick Sundich, February 17, 2023

QBE (ASX:QBE) managed to grow its FY22 NPAT by $20m in spite of difficult market conditions. It isn’t an easy time to be an insurer, but the company’s premium growth was enough to counter the market. 

 

No time to do stock research, but you still want to invest?

 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 
QBE records a solid result

QBE’s FY22 NPAT was US$770m, up from US$750m in FY21, and it recorded a 10.5% cash Return on Equity. 

The company paid a total dividend of 3c per share, representing a payout ratio of 48% of adjusted cash profit and a 2.9% yield at yesterday’s closing share price. 

 

QBE (ASX:QBE) 1-year share price chart, log scale (Source: TradingView)

 

Premiums make up for difficult conditions

There were difficult economic conditions during 2022 with heightened inflation, geopolitical tensions, elevated catastrophic activity and poor financial market conditions.

Indeed, QBE recorded an investment loss of $776m after a $122m return in FY21. This was due to unrealised losses associated with the significant increase in bond yields.  

However, the insurer’s customers see the need for its service more than ever and were willing to pay more for an additional layer of protection. 

The company recorded gross written premium growth of 13% and a groupwide renewal increase of 7.9%. 

Looking to FY23, the company promised gross written premium growth of mid to high single digits. 

 

Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
 
With price targets, buy ranges, stop loss levels and Sell alerts too.

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

Recent Posts

ASX Health stocks

5 ASX Health stocks to add to your porfolio

5 ASX Health Stocks Stuart Roberts from Stocks Down Under discussed the potential promise of biotech, sharing his perspectives about…

BHP wants to buy Anglo American

BHP wants to buy Anglo American, but what would the potential $60bn deal mean?

In what was meant to be a quiet week on the markets, investors learned yesterday that BHP wants to buy…

ASX resources juniors

Here are 5 ASX resources juniors with projects in unusual locations

ASX resources juniors live and die by many things, but project location is one of them. The majority have projects…